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ABSTRACT
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related 
deaths worldwide, and it has been linked to radiation exposure. As a well-defined 
oncogene, wild-type p53-induced phosphatase 1 (WIP1) plays an inhibitory role in 
several tumor suppressor pathways, including p53. WIP1 is amplified and overexpressed 
in many malignancies, including HCC. However, the underlying mechanisms remain 
largely unknown. Here, we show that low-dose ionizing radiation (IR) induces miR-29c 
expression in female mouse liver, while inhibiting its expression in HepG2, a human 
hepatocellular carcinoma cell line which is used as a model system in this study. miR-
29c expression is downregulated in human hepatocellular carcinoma cells, which is 
inversely correlated with WIP1 expression. miR-29c attenuates luciferase activity 
of a reporter harboring the 3’UTR binding motif of WIP1 mRNA. Ectopic expression 
of miR-29c significantly represses cell proliferation and induces apoptosis and G1 
arrest in HepG2. In contrast, the knockdown of miR-29c greatly enhances HepG2 
cell proliferation and suppresses apoptosis. The biological effects of miR-29c may be 
mediated by its target WIP1 which regulates p53 activity via dephosphorylation at 
Ser-15. Finally, fluorescence in situ hybridization (FISH) and immunohistochemical 
analyses indicate that miR-29c is downregulated in 50.6% of liver carcinoma tissues 
examined, whereas WIP1 is upregulated in 45.4% of these tissues. The expression of 
miR-29c inversely correlates with that of WIP1 in HCC. Our results suggest that the 
IR-responsive miR-29c may function as a tumor suppressor that plays a crucial role in 
the development of liver carcinoma via targeting WIP1, therefore possibly representing 
a target molecule for therapeutic intervention for this disease.
INTRODUCTION
HCC is the most common primary liver malignancy 
in adults and the third most common cause of cancer-related 
deaths worldwide [1, 2]. In Canada, HCC is a growing 
problem. Based on data from the Canadian Cancer Registry, 
age-adjusted liver cancer incidence rose to 15.4 per 100,000 
for the period 2006–2010 [3], three times the incidence for 
the period 1976–1980. The primary risk factors for HCC 
may be chronic hepatitis B (HBV) and C virus (HCV) 
infections and cirrhosis because 78% of HCC cases and 
57% of liver cirrhosis cases are caused by chronic infection 
with HBV and HCV [4]. Most solid cancers have been 
linked to radiation [5], including liver cancer. The dose-
response relationship between radiation and liver cancer 
has been clinically verified in primary liver cancer cases 
and implicated in histological analyses [6].
MicroRNAs (miRNAs/miRs) are small noncoding 
RNA molecules that negatively regulate gene expression 
at the post-transcriptional level through either translational 
repression or mRNA cleavage [7, 8]. Approximately 
60% of human protein-coding genes are targets of 
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miRNAs [9]. These molecules may function as tumor 
suppressors or oncogenes [10–12] that play crucial roles 
in diverse biologic and pathologic processes, such as 
cell proliferation, differentiation, and apoptosis [7, 13]. 
miRNAs are also involved in genotoxic stress responses. 
We have recently shown that IR causes a profound 
dysregulation of miRNA expression in exposed tissues and 
organs, such as the thymus, mammary gland, and liver. 
Among miRNAs, miR-29c is significantly influenced in 
the IR-exposed liver tissue.
miR-29c belongs to the miR-29 family which 
includes three other members in humans: miR-29a, 
miR-29b-1, and miR-29b-2 [14]. Since miR-29b-1 and 
miR-29b-2 have identical mature sequences, they are 
collectively called miR-29b [14]. miR-29a and miR-
29b-1 are transcribed together as a polycistronic primary 
transcript [15, 16], while miR-29b-2 and miR-29c are 
transcribed together. The members of this family may 
function as tumor suppressors, and a loss of function 
of these miRNAs may contribute to tumorigenesis and 
metastasis. A large body of evidence has demonstrated that 
miR-29c is frequently reduced in human malignancies, 
including gastric cancer [17], metastatic lung cancer [18], 
chronic lymphocytic leukemia [19], metastatic medullary 
thyroid carcinoma [20], peripheral nerve sheath tumors 
[21], hepatocellular carcinoma [22, 23], meningioma [24], 
and nasopharyngeal [25, 26] and esophageal squamous 
cell carcinomas [27].
WIP1 (also known as PP2Cδ), a nuclear serine/
threonine phosphatase encoded by protein phosphatase 
magnesium-dependent 1 delta (PPM1D) [28] belongs to 
the Ser/Thr PP2C family of phosphatases. The members 
in this evolutionarily conserved family are key players in 
the regulation of cellular stress response [28, 29]. WIP1 is 
not only a direct transcriptional target of tumor suppressor 
p53 but also an important negative regulator of p53, thus 
forming a negative regulatory feedback loop [30, 31]. 
The negative regulatory effect of WIP1 on p53 may be 
primarily attributed to its ability to dephosphorylate p53 
Ser-15 [32].
miR-29c was bioinformatically predicted to target 
WIP1. However, the expression of miR-29c in response to 
IR in the liver and the role of miR-29c in hepatocellular 
carcinogenesis are not completely understood yet. 
We therefore explored the expression of miR-29c in 
liver tissue of mice exposed to IR and determined 
the contribution of miR-29c to the development of 
hepatocellular carcinoma. The data presented in this paper 
indicate that low-dose IR triggers a profound induction of 
miR-29c expression in mouse liver tissue. We also show 
that miR-29c is downregulated in both mouse hepatoma 
and human hepatocellular carcinoma cells. The ectopic 
expression of miR-29c inhibits hepatocellular carcinoma 
cell proliferation and induces apoptosis and G1 cell cycle 
arrest. In contrast, the knockdown of miR-29c promotes 
cell proliferation and represses apoptosis. We provide 
evidence that miR-29c directly targets wild-type p53-
induced phosphatase 1 (WIP1). Furthermore, the FISH 
analysis shows that miR-29c was downregulated in 
50.6% of the human hepatocellular carcinoma specimens 
examined (n = 255). Immunohistochemical staining 
indicates that WIP1 was overexpressed in 45.4% of the 
hepatocellular carcinoma tissues analyzed (n = 249).
RESULTS
Low-dose IR triggers a differential expression 
of miR-29c in female mouse liver and human 
HepG2 cells
Our previous studies indicated that IR triggered a 
profound, sex-specific deregulation of microRNAome in 
the spleen of C57BL/6 mice [33]. To explore miRNAs that 
are differentially expressed in liver tissues in response to 
IR, 8-week-old female C57BL/6 mice were exposed to 
different doses of X-ray and sacrificed 96 hours after 
irradiation. The microRNA microarray analysis showed 
that miR-29c was remarkably elevated in response to low-
dose IR (Figure 1A and 1B).
These results were validated by quantitative real-
time RT-PCR (qRT-PCR, Figure 1C). qRT-PCR also 
showed a differential expression of miR-29c in the liver 
tissue of mice exposed to IR at the indicated time points 
(supplementary Figure S1). To explore an expression 
pattern of miR-29c in human hepatocellular carcinoma 
HepG2 cells in response to low-dose IR, HepG2 cells were 
exposed to 0.3 Gy X-ray, and the expression of miR-29c 
was then determined. qRT-PCR indicated that low-dose IR 
had no effect on the expression of miR-29c in HepG2 cells 
at 96 hours post IR, whereas IR did suppress its expression 
at 12 and 24 hours after IR (Figure 1D). To understand 
the mechanism involved, we examined the expression of 
argonaute RISC catalytic component 2 (AGO2). Western 
blot analysis showed that AGO2 was downregulated at 12 
and 24 hours post IR and upregulated at 96 hours after it 
(Figure 1E), which may contribute to the IR-responsive 
miR-29c expression in HepG2 cells.
WIP1 is a novel direct target of miR-29c
To determine the role of IR-responsive miR-29c in 
liver cancer, we measured the expression of miR-29c in 
hepatocellular carcinoma cells. qRT-PCR showed that miR-
29c was significantly downregulated in both mouse (Hepa 
1–6) and human (HepG2, C3A) hepatocellular carcinoma 
cells (Figure 2A and 2B; p < 0.01), which was consistent 
with the previous report [23]. To better understand the role 
of miR-29c and identify its novel targets, we performed 
a bioinformatics analysis where WIP1 was predicted as 
a potential target of miR-29c (Figure 2C). Western blot 
analysis showed that WIP1 was upregulated in two of 
the examined human hepatocellular carcinoma cell lines 
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Figure 1: A differential expression of miR-29c in liver tissues of female mice exposed to IR and human HepG2 cells.  
(A and B) Total RNA isolated from IR-exposed female mouse liver tissues 96 hours post-irradiation was subjected to the microRNA 
microarray. (C) Total RNA was isolated from liver tissues of female mice exposed to IR 96 hours post irradiation, and the levels of miR-
29c were examined by real-time RT-PCR. (D) Total RNA isolated from human hepatocellular carcinoma HepG2 cells at the indicated time 
points after exposure to low-dose X-ray (0.3 Gy) was subjected to real-time RT-PCR using miR-29c primer. (E) Whole cellular lysate 
prepared from HepG2 cells at the indicated time points after exposure to low-dose X-ray (0.3 Gy) was subjected to Western blotting with a 
specific antibody to AGO2. The asterisk indicates p < 0.05.
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Figure 2: miR-29c is downregulated in liver carcinoma cells and directly targets WIP1. (A and B) Total RNA isolated from 
an epithelial cell line NMuLi derived from normal mouse liver, a mouse hepatoma cell line Hepa 1–6, human hepatocellular carcinoma 
cell lines HepG2 and C3A, and human normal liver tissue (HNLT) was subjected to real-time RT-PCR analysis using the miR-29c primer 
assays. (C) WIP1, a predicted target of miR-29c. (D and E) The whole lysate was prepared from NMuLi, Hepa 1–6, C3A and HepG2 cell 
lines, and HNLT; Western blot analysis was performed using antibodies against BCL2, MCL1, SIRT1, and WIP1. (F) Sequences of the 
wild-type and mutant WIP1 3′UTR reporters were used in this study; bold Italic letters indicate the mutated nucleotides. (G) HEK293 cells 
were transiently transfected with either the Luc-WT-WIP1 or Luc-MT-WIP1 reporter in combination with the indicated concentration of 
miR-29c; the luciferase activity was detected according to the manufacturer’s instructions. The asterisk indicates p < 0.05; double asterisks 
indicate p < 0.01; triple asterisks indicate p < 0.001.
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(Figure 2E), which was inversely correlated with miR-29c 
expression (Figure 2B), although WIP was downregulated 
in mouse Hepa 1–6 cells (Figure 2D). To confirm that 
miR-29c directly targets WIP1, we generated luciferase 
reporters bearing either the wild-type or mutant 3′ UTR of 
WIP1 (Figure 2F). The luciferase assay indicated that miR-
29c significantly reduced the activity of wild-type WIP1 
luciferase in a dose-dependent manner, while this reduction 
was abolished in the mutant WIP1 reporter (Figure 2G; 
p < 0.05). These results suggest that WIP1 is a direct target 
of miR-29c. Because oncogene sirtuin 1 (SIRT1) and two 
antiapoptotic molecules, B-cell CLL/lymphoma 2 (BCL2) 
and myeloid cell leukemia sequence 1 (MCL1), have been 
identified as direct targets of miR-29c [22, 23], we also 
analyzed their expression in Hepa 1–6, C3A, and HepG2 
cell lines. Western blot analysis showed that MCL1 was 
overexpressed in two human hepatocellular carcinoma cell 
lines, while SIRT1 was elevated in all the examined cell 
lines (Figure 2D and 2E).
miR-29c may function as a tumor suppressor in 
hepatocellular carcinoma
Next, we determined the role of miR-29c in liver 
carcinogenesis using HepG2 as a model system. With 
transient transfection, the MTT assay showed that miR-
29c significantly suppressed hepatocellular carcinoma cell 
proliferation (Figure 3A and 3B; p < 0.05). The ectopic 
expression of miR-29c also induced apoptosis and G1 
cell cycle arrest (Figure 3C and 3D). Conversely, miR-
29c inhibitor significantly promoted liver carcinoma cell 
proliferation (Figure 3E and 3F; p < 0.05) and slightly 
inhibited apoptosis (Figure 3G), although it had no effect 
on cell cycle (data not shown). To explore the underlying 
mechanism, we determined the expression of WIP1 and 
its target, phosphorylated p53 at Ser-15 [32]. Western blot 
analysis indicated that miR-29c reduced WIP1 expression 
(Figure 3H, the left panel), leading to an elevation in 
phosphorylated p53 at Ser-15. Conversely, miR-29c 
inhibitor promoted WIP1 expression (Figure 3H, the 
right panel), resulting in a decrease in the phosphorylated 
p53. The enforced expression of miR-29c also led to an 
induction in p21 and p27 expression and an increase in 
the cleaved caspase 3 (Figure 3H, the left panel). miR-29c 
inhibitor, however, had no effect on the expression of p21 
and p27 and the levels of cleaved caspase 3, but it reduced 
the expression of BAX (Figure 3H, the right panel). These 
results suggest that miR-29c plays a suppressive role in 
hepatocellular carcinoma by targeting WIP1.
Downregulated miR-29c may contribute to the 
upregulation of WIP1 in liver carcinoma tissues
Next we performed the bioinformatics analysis of the 
correlation between miR-29c and WIP1 levels using a number 
of publically available deep sequencing datasets. A very 
strong inverse correlation was found in HeLa cells, although 
only a weak inverse correlation was observed in three Cancer 
Genome Atlas datasets (kidney renal clear cell carcinoma, 
lung squamous cell carcinoma, and rectum adenocarcinoma). 
To validate the inverse correlation between miR-29c and 
WIP1 in a large number of samples, we determined the 
expression of these two molecules in liver carcinoma tissue 
arrays and subsequently performed a correlation analysis. 
The FISH analysis showed that miR-29c was downregulated 
in 50.6% (n = 255) of the liver carcinoma tissues examined 
(Figure 4A and 4B). However, the immunohistochemical 
analysis revealed that WIP1 was upregulated in 45.4% 
(n = 249) of the liver carcinoma tissues (Figure 4A and 4B). 
The expression of miR-29c was inversely correlated with 
that of WIP1 in the tissues (Pearson r = −0.8488). The 
upregulated WIP1 was located primarily in the cytoplasm 
(Figure 4C). Frequently, WIP1 was overexpressed in the 
progression of this disease (Figure 4D).
DISCUSSION
Although low-dose IR has been shown to improve 
the efficacy of chemotherapeutic agents [34, 35], the 
potential contribution of low-dose IR to enhancing 
radiation-induced tumor-cell killing is a matter of debate. It 
has been indicated that in radiotherapy treatment, smaller 
fractions (< 0.5 Gy) delivered before larger fractions (> 
0.5 Gy) lead to a small increase in cell kill in vitro [36]. 
However, in some in vivo studies that used glioblastoma 
xenografts, three small fractions (0.4 Gy per day) failed to 
show an improved outcome [37]. Furthermore, low-dose 
radiation exposure has been linked to an increased cancer 
risk [38].
This study for the first time reveals that low-dose 
IR induces miR-29c expression in female mouse liver. 
Interestingly, we noted that the expression pattern of miR-
29c in the IR-exposed human hepatocellular carcinoma 
cell line HepG2 appeared to differ from that in female 
liver of mice exposed to IR because it was upregulated 
in normal female mouse liver and downregulated in 
liver carcinoma HepG2 cells in response to low-dose IR 
(Figure 1C and 1D). Our results implicate that low-dose IR 
may have a protective effect on malignant transformation 
in normal liver and a promotive effect in liver carcinoma, 
which argues for the potential of low-dose IR to slightly 
increase cell killing (including cancer cells) in vitro [36]. 
Although the mechanism is still unclear, alterations in 
AGO2 expression may contribute to the low-dose IR-
triggered differential expression of miR-29c.
We have found that miR-29c is downregulated in 
liver carcinoma cell lines and tissues, which is consistent 
with previous reports showing frequent reductions of 
miR-29c in human malignancies, including hepatocellular 
carcinomas [22, 23]. It has been shown that the 
re-induction of miR-29c suppresses cell proliferation 
[18, 22, 27], migration and invasion [18, 21, 25], induces 
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(Continued )
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apoptosis [23] and attenuates tumor xenograft growth 
in vivo [17, 23, 27]. We also provide strong evidence for 
the tumor-suppressive role of miR-29c in the development 
of hepatocellular carcinoma. The ectopic expression of 
miR-29c significantly suppresses liver carcinoma cell 
proliferation and induces apoptosis and cell cycle arrest 
(Figure 3). In contrast, the knockdown of miR-29c 
promotes liver carcinoma cell growth and inhibits cell 
apoptosis.
Although we (and other authors) have clearly 
demonstrated the suppressive role of miR-29c in liver 
carcinoma, the underlying mechanisms (key target 
molecules of miR-29c, in particular) remain largely 
unknown. This study has, for the first time, revealed 
that WIP1 is a direct target of miR-29c, and it has also 
disclosed an inverse correlation between miR-29c 
expression and WIP1 levels in liver carcinoma cell lines 
and tissues. We have shown that the ectopic expression 
of miR-29c reduces the levels of WIP1; as a result, the 
phosphorylated p53 at Ser-15 is elevated in HepG2 cells 
(Figure 3H, the left panel). This may contribute to miR-
29c-induced apoptosis and cell cycle arrest (Figure 3C 
and 3D) [39]. Conversely, miR-29c inhibitor increases 
the expression of WIP1, thus leading to a reduction in the 
phosphorylated p53 at Ser-15 (Figure 3H, the right panel). 
These findings are consistent with previous reports [32]. 
Figure 3: The suppressive role of miR-29c in hepatocellular carcinogenesis. (A) HepG2 cells were transfected with either 
100 nM miR-29c or negative control; total RNA isolated from these cells at the indicated time points was subjected to real-time RT-PCR 
using the miR-29c primer assays. (B) HepG2 cells transfected with either 100 nM miR-29c or negative control were re-plated in 96-well 
plates; the MTT assay was carried out as described in “Materials and Methods”. (C) HepG2 cells transfected with either 100 nM miR-29c 
or negative control were harvested for apoptosis analysis at the indicated time points as described in “Materials and Methods”; the lower 
panel represented the average values of independent experiments. (D) 96 hours post transfection, HepG2 cells transfected with either 
100 nM miR-29c or negative control were harvested for cell cycle analysis as described in “Materials and Methods”. (E) HepG2 cells 
were transfected with either 100 nM miR-29c inhibitor or negative control; total RNA isolated from these cells at the indicated time points 
was subjected to real-time RT-PCR using the miR-29c primer assays. (F) HepG2 cells transfected with either 100 nM miR-29c inhibitor 
or negative control were re-plated in 96-well plates; the MTT assay was carried out as described in “Materials and Methods”. (G) HepG2 
cells transfected with either 100 nM miR-29c inhibitor or negative control were harvested for apoptosis analysis at the indicated time points 
as described in “Materials and Methods”; the lower panel represented the average values of independent experiments. (H) 96 hours post 
transfection, the whole cellular lysate prepared from HepG2 cells transfected with either 100 nM miR-29c mimic (the left panel), miR-29c 
inhibitor (the right panel), or negative control was subjected to Western blotting with antibodies to BAX, cleaved caspase 3, p21, p27, p53, 
p-p53 and WIP1. The asterisk indicates p < 0.05.
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Figure 4: The expression of miR-29c and WIP1 in hepatocellular carcinoma tissues. (A) Representatives of hsa-miR-29c and 
WIP1 stainings in the same sections of liver carcinoma tissue arrays. (B) Statistical analyses of hsa-miR-29c and WIP1 expression in liver 
carcinoma tissues. (C) Representatives of WIP1 staining in normal liver and carcinoma tissues. (D) The frequency of WIP1 expression in 
the progression of liver carcinoma “c” indicates cytoplasmic staining.
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In addition to miR-29c, another well-defined tumor 
suppressor, miR-34a, is also transcriptionally regulated 
by the phosphorylated p53 at Ser-15 [40], suggesting 
an important role of p53 Ser-15 phosphorylation in 
transcriptional regulation of tumor suppressor miRNAs. 
Although this is the first description of miR-29c in the 
maintenance of p53 activity via targeting WIP1, other 
studies have indicated that miR-29 may also activate p53 
by targeting p85 alpha and CDC42 [41]. As expected, the 
enforced expression of miR-29c induced the expression 
of p53 transcriptional targets p21 and p27 (Figure 3H, the 
left panel), the cyclin-dependent kinase inhibitors, due to 
the upregulation in p53 Ser15 phosphorylation [42]. This 
may contribute to the miR-29c-induced G1 arrest [43] 
(Figure 3D). Interestingly, the ectopic expression of miR-
29c also caused an elevation in cleaved caspapse-3 with 
no effect on BAX (Figure 3H, the left panel), although a 
Bax-dependent caspase-3 activation has been shown to be 
essential for p53-induced apoptosis in neurons [44]. The 
upregulation of cleaved caspase-3, however, may play a 
crucial role in miR-29c-induced apoptosis (Figure 3C). 
Unlike p21 and p27, a miR-29c inhibitor remarkably 
attenuated BAX expression (Figure 3H, the right panel) 
due to the reduction in p53 Ser15 phosphorylation. The 
downregulated BAX may contribute to the miR-29c 
inhibitor-mediated reduction in apoptosis (Figure 3G) 
through the activation of caspases other than caspase-3, 
for instance, capase-7 [45]. To date, many other oncogene 
mRNAs have been identified as targets of miR-29c, such 
as cyclin D2 (CCND2) [17], matrix metalloproteinase-2 
(MMP2) [17, 18, 21], integrin β1 [18], mammalian SIRT1 
[22], BCL2 [23], MCL1 [23], T-cell lymphoma invasion and 
metastasis 1 (TIAM1) [25], and cyclin E [27]. Interestingly, 
recent studies have found that miR-29c enhances the 
sensitivities of human nasopharyngeal carcinoma to both 
chemotherapy and radiotherapy [46]. miR-29 has also been 
linked to aging. Recently, a comprehensive study indicated 
an miR-29-induced cellular senescence in aging muscles 
through targeting multiple signaling pathways, including 
p85a, IGF-1 and B-myb [47].
In addition to p53, WIP1 can also dephosphorylate 
several other DNA damage-responsive proteins, 
including those of the ataxia-telangiectasia mutated 
gene (ATM), the ataxia-telangiectasia and Rad3-related 
protein (ATR), checkpoint kinase 1 (CHK1), checkpoint 
kinase 2 (CHK2), and p38 MAPK [48]. Due to its 
distinctive oncogenic properties mediated by inhibitory 
functions on the above mentioned tumor suppressor 
pathways [49], WIP1 has been linked to cancer. WIP1 is 
frequently amplified and overexpressed in neuroblastoma, 
medulloblastoma, breast, pancreatic, ovarian, and gastric 
carcinomas [50–55]. WIP1 was overexpressed in 45.4% 
of our liver carcinoma tissue samples, whereas miR-29c 
was downregulated in 50.6% of the samples (Figure 4A 
and 4B). We have concluded that the expression level 
of miR-29c is inversely correlated with that of WIP1 
in both normal liver and carcinoma tissues (Figure 4A 
and 4B). For the first time, we have established a causal 
relationship between the downregulation of miR-29c 
and the upregulation of WIP1 in liver carcinomas. We 
have also noted that the percentage of liver carcinoma 
tissues with WIP1 overexpression increases slightly with 
the progression of this disease (Figure 4D), implicating 
that the overexpressed WIP1 may contribute primarily 
to the development of liver carcinoma. Over half of 
human malignancies contain mutations in p53, including 
29% HCC reported in Japanese patients (n = 169) [56]; 
however, a sizable fraction of HCC carries wild-type 
p53. Our results may imply an important role of the 
overexpressed WIP1 in liver carcinomas with wild-
type p53 via inactivating p53 functions. These findings 
make WIP1 a potent therapeutic target against HCC. 
Although this is the first report of the existence of an 
inverse correlation between cellular levels of miR-29c 
and WIP1, the downregulation of miR-29c has been 
found in medulloblastoma [57], glioma [58] and gastric 
cancer [59]; however, the upregulation of WIP1 has also 
been reported in these carcinomas [60–62], implicating a 
possible inverse correlation between these two molecules. 
Further studies are needed to dissect the role of miR-29c 
and WIP1 in carcinogenesis and cancer.
In summary, low-dose IR-responsive miR-29c is 
downregulated in liver carcinoma cells and tissues. miR-
29c functions as a tumor suppressor that plays a crucial 
role in the development of hepatocellular carcinoma via 
targeting WIP1 (Figure 5A and 5B), and it may represent a 
target molecule for therapeutic intervention for this disease.
MATERIALS AND METHODS
Animal irradiation
Male and female 8-week-old C57BL/6 mice 
purchased from Charles River Laboratories (Quebec, 
Canada) were randomly assigned to different treatment 
groups. The control group was sham-treated (0/0), and 
the treatment groups were characterized as follows: low-
dose group (0.3/0)—mice were exposed to only 0.3 gray 
(Gy) irradiation on day 0; high-dose group (0/3)—mice 
were exposed to only 3 Gy acute irradiation on day 4; 
priming group (0.3/3)—mice were exposed to both 0.3 Gy 
priming irradiation on day 0 and 3 Gy acute irradiation on 
day 4. Twenty mice per group (10 males and 10 females) 
were sacrificed at 6 hours, 96 hours, and 2 weeks after 
irradiation. Liver specimens were frozen immediately and 
stored at –80°C or fixed in 10% neutral buffered formalin 
and embedded in paraffin. Handling and care of animals 
were in accordance with the recommendations of the 
Canadian Council for Animal Care and Use. Procedures 
were approved by the University of Lethbridge Animal 
Welfare Committee. Animals were housed in a virus-free 
facility and given food and water ad libitum.
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MicroRNA profiling
Three replicates were used for each group described 
in the “Animal irradiation” section. Total RNA was 
isolated from the liver tissues of IR-exposed mice at 
96 hours post IR using TRIzol reagent (Invitrogen, San 
Diego, CA) according to the manufacturer’s instructions. 
MicroRNA profiling, clustering and data analysis were 
carried out by LC Sciences (Houston, USA).
Cell culture
Human embryonic kidney 293 (HEK293) cells 
were grown in DMEM/High Glucose (Thermo Scientific, 
Waltham, MA) supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin (P/S). 
Human hepatocellular carcinoma cell lines HepG2 and 
C3A were cultured in ATCC-formulated EMEM (ATCC, 
Manassas, VA) supplemented with 10% FBS and 1% P/S. 
The normal mouse liver epithelial cell line NMuLi and 
the mouse hepatoma cell line Hepa 1–6 were grown in 
ATCC-formulated DMEM (ATCC) supplemented with 
10% FBS and 1% P/S. All cells were cultured at 37°C in a 
humidified atmosphere of 5% CO2.
MicroRNA real-time RT-PCR
Total RNA isolated from liver tissue of mice 
exposed to IR, normal human liver tissue (Amsbio, 
Cambridge, MA), NMuLi, Hepa 1–6, HepG2, and C3A 
cell lines was subjected to real-time RT-PCR using the 
miScript II RT Kit (QIAGEN, Chatsworth, CA), miR-29c 
miScript primer assays, and the miScript SYBR® Green 
PCR Kit per the manufacturer’s instructions. RNU6–2 was 
used as a loading control.
The generation of luciferase reporter plasmid 
constructs
Luciferase miR-29c target reporters were generated 
as described previously [12]. Briefly, oligos corresponding 
to portions of the 3′UTRs of WIP1 were synthesized, 
annealed, and cloned downstream of the luciferase gene in 
the pGL3-Basic vector between Xba I and EcoR I (a linker 
introduced by Mr. James Meservy) to generate Luc-WT-
WIP1 and Luc-MT-WIP1 reporters. The sequence identity 
was confirmed by automatic sequencing. Oligo sequences 
were as follows: WIP1 3′UTR-WT1: 5′-/5Phos/CTA 
GAC TTG CTA TTT CAA TAA CAG ATG GTG CTG 
Figure 5: A model for the suppressive role of miR-29c in liver carcinoma. (A) In normal liver cells, the normally expressed 
miR-29c may contribute to the maintenance of normal p53 activity via targeting WIP1 phosphatase, thus maintaining a normal growth, 
proliferation, and apoptosis. (B) In liver carcinoma cells, miR-29c is downregulated due to promoter hypermethylation, leading to the 
overexpression of WIP1 that inactivates p53 by dephosphorylating p53 at Ser-15, which results in the promotion in cell proliferation and 
reduction in apoptosis that may contribute to the development of liver carcinoma.
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CTG-3′, WIP1 3′UTR-WT2: 5′-/5Phos/AAT TCA GCA 
GCA CCA TCT GTT ATT GAA ATA GCA AGT-3′ WIP1 
3′UTR-MTa: 5′-/5Phos/CTA GAC TTG CTA AAA AAA 
TAA CAG AAA AAA AAG CTG-3′, WIP1 3′UTR-MTb: 
5′-/5Phos/AAT TCA GCT TTT TTT TCT GTT ATT TTT 
TTA GCA AGT-3′.
The transient transfection and luciferase assay
HEK293 cells grown to 90% confluence in 
6-well plates in antibiotic-free DMEM/High Glucose 
(Thermo Scientific) containing 10% FBS were transiently 
cotransfected with either 0.5 μg of Luc-WT-WIP1 or 
Luc-MT-WIP1 reporter, 5-ng pRL-TK plasmid, and the 
indicated concentration of hsa-miR-29c mimic (QIAGEN) 
using Lipofectamine 3000 (Invitrogen) according to the 
manufacturer’s instructions. Twenty-four hours after trans-
fection, the cells were harvested, the relative luciferase 
activity was measured by the Dual-Luciferase Reporter 
Assay System (Promega, Madison, WI) using a luminometer 
(FLUOstar Omega, BMG LABTECH, Germany) and the 
wild-type Firefly luciferase data were normalized to mutant 
Firefly luciferase.
The transient transfection and MTT assay
HepG2 cells grown to 90% confluence were 
transiently transfected with either 100 nM miR-29c mimic, 
100 nM miR-29c inhibitor, or 100 nM AllStars negative 
control (QIAGEN) using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s instructions. Twenty-
four hours after transfection, 3.0 × 103 HepG2 cells were 
plated in 96-well plates. The 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays 
were carried out using a Cell Proliferation Kit I (Roche 
Diagnostics GmbH, Mannheim, Germany) according to 
the manufacturer’s instructions. The spectrophotometric 
absorbance of samples was measured at 595 nm using a 
microtiter plate reader (FLUOstar Omega).
Cell cycle and apoptosis analyses
HepG2 cells grown to 90% confluence were 
transiently transfected with either 100 nM miR-29c mimic, 
a 100 nM inhibitor, or 100 nM AllStars negative control. 
At 96 hours post-transfection, the cells were harvested for 
cell cycle and apoptosis analyses that were performed with 
a BD FACSCanto™ II Flow Cytometer (BD Biosciences, 
Franklin Lakes, NJ) using a propidium iodide staining 
solution and a BD Pharmingen™ V-FITC Annexin 
Apoptosis Detection Kit II (BD Biosciences) according to 
the manufacturer’s instructions.
Bioinformatics
Potential hsa-miR-29c targets were predicted by 
both TargetScan and RNAhybrid software applications. 
The correlation between miR-29c and WIP1 was predicted 
using miRGator (http://mirgator.kobic.re.kr/index.html).
Western blot analysis
NMuLi, Hepa 1–6, C3A, and HepG2 cells or 
HepG2 cells transfected with either 100 nM miR-29c 
mimic, a 100 nM inhibitor, or 100 nM AllStars negative 
control were washed twice with ice-cold PBS and lysed 
in radioimmunoprecipitation assay buffer (RIPA). Protein 
isolated from human normal liver tissue (HNLT) purchased 
from AMSBio (AMS Biotechnology, Cambridge, MA) 
served as a normal control for human cell lines. 30–60 μg 
of protein per sample was electrophoresed on either 8% or 
10% SDS-PAGE and electrophoretically transferred to a 
polyvinylidene difluoride (PVDF) membrane (Amersham 
Hybond® P, GE Healthcare, Buckinghamshire, UK) at 4°C 
for 1.5 hours. Blots were incubated for 1 hour with 5% 
nonfat dry milk to block nonspecific binding sites, and 
then they were incubated overnight at 4°C with polyclonal/
monoclonal antibodies against BAX, BCL2, MCL1, 
SIRT1, p27, p–p53 (Santa Cruz Biotechnology, Dallas, TX) 
or cleaved caspase 3, p21, p53 (Cell Signaling Technology, 
Danvers, MA), AGO2, or WIP1 (Abcam, Cambridge, UK). 
The immunoreactivity was detected using a peroxidase-
conjugated antibody and visualized by an ECL Plus 
Western Blotting Detection System (GE Healthcare). The 
blots were stripped before reprobing with an antibody to 
actin or GAPDH (Santa Cruz Biotechnology).
Fluorescence in situ hybridization
Hsa-miR-29c expression in liver carcinoma 
specimens (LVC481 and LVC2281 tissue arrays; Pan-
tomics, Richmond, CA) was determined by FISH, as 
detailed elsewhere [63]. After deparaffinization, the sections 
were prehybridized for 20 minutes at 55°C followed by 
1 hour hybridization at the same temperature with a 1:1000 
dilution of a miRCURY LNA™ hsa-miR-29c detection 
probe (Exiqon, Vedbaek, Denmark). After washing, the 
sections were blocked for 1 hour with a blocking solution 
and incubated with a 1:1000 dilution of anti-Digoxigenin-
Fluorescein, Fab fragments (Roche, Basel, Switzerland) at 
4°C overnight. Then research scientists and a pathologist 
independently analyzed the stained tissue sections.
Staining intensity was the criterion used for 
quantitating immunofluorescence staining. A range of 0 
to 3 was used for classifying the intensity: 0 = absence of 
staining; 1 = weak staining; 2 = moderate staining; and 
3 = intense staining.
Immunohistochemical analysis
The expression of WIP1 in the liver carcinoma 
specimens (LVC481 and LVC2281 arrays; Pantomics) 
was determined by immunohistochemical staining using 
a mouse monoclonal antibody to WIP1 (Santa Cruz 
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Biotechnology, Dallas, TX) according to the Biocare 
Medical instructions for immunohistochemistry. The 
stained tissue sections were analyzed independently by a 
pathologist and research scientists in a blind manner.
The criteria used for quantitating immunohisto-
chemical staining included the staining intensity and 
percentage of cells stained. A range of 0 to 3 was used to 
classify the intensity of staining: 0 = absence of staining; 
1 = weak staining; 2 = moderate staining; and 3 = intense 
staining. The numbers of cells stained were recorded 
according to the following classification: a, < 25% of cells 
stained; b, 25%–50% of cells stained; c, 51%–75% of cells 
stained; and d, > 75% of cells stained.
Statistical analysis
The Student’s t-test was used to determine the 
statistical significance of differences between groups 
in hsa-miR-29c and WIP1 expression, cell growth, cell 
cycle, apoptosis, luciferase activity, and the correlation of 
WIP1 with HCC clinical grades. The Pearson correlation 
was used to determine the statistical significance in has-
miR-29c and WIP1 expression between normal and tumor 
tissues. p < 0.05 was considered significant.
ACkNOWLEDGMENTS
This study was supported by the Canadian Institutes 
for Health Research and the Department of Energy Low 
Dose Radiation program grants to Dr. Olga Kovalchuk. 
Mieke Heyns was supported by the NSERC Undergraduate 
Student Research Award. We thank Dr. Valentina Titova 
for proof-reading the manuscript.
CONFLICTS OF INTEREST
No potential conflicts of interest were disclosed.
REFERENCES
1. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, 
Fong Y, et al. Hepatocellular carcinoma: consensus recom-
mendations of the national cancer institute clinical trials 
planning meeting. J Clin Oncol. 2010; 28:3994–4005.
2. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, 
Omata M, et al. Hepatocellular carcinoma (HCC): a global 
perspective. J Clin Gastroenterol. 2010; 44:239–45.
3. Pocobelli G, Cook LS, Brant R, Lee SS. Hepatocellular car-
cinoma incidence trends in Canada: analysis by birth cohort 
and period of diagnosis. Liver Int. 2008; 28:1272–9.
4. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, 
Bell BP. The contributions of hepatitis B and hepatitis C 
virus infections to cirrhosis and primary liver cancer world-
wide. J Hepatol. 2006; 45:529–38.
5. Gilbert ES. Ionizing radiation and cancer risks: what have we 
learned from epidemiology? Int J Radiat Biol. 2009; 85:467–82.
6. Cologne JB, Tokuoka S, Beebe GW, Fukuhara T, 
Mabuchi K. Effects of radiation on incidence of primary 
liver cancer among atomic bomb survivors. Radiat Res. 
1999; 152:364–73.
7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, 
and function. Cell. 2004; 116:281–97.
8. Bartel DP. MicroRNAs: target recognition and regulatory 
functions. Cell. 2009; 136:215–33.
9. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mam-
malian mRNAs are conserved targets of microRNAs. 
Genome Res. 2009; 19:92–105.
10. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs 
as oncogenes and tumor suppressors. Dev Biol. 2007; 
302:1–12.
11. Koturbash I, Zemp FJ, Pogribny I, Kovalchuk O. Small 
molecules with big effects: the role of the microRNAome 
in cancer and carcinogenesis. Mutat Res. 2011; 722:94–105.
12. Li D, Ilnytskyy Y, Kovalchuk A, Khachigian LM, 
Bronson RT, Wang B, et al. Crucial role of early growth 
response-1 in the transcriptional regulation of miR-20b in 
breast cancer. Oncotarget. 2013; 4:1373–87.
13. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, 
Hill JA, et al. The endothelial-specific microRNA miR-
126 governs vascular integrity and angiogenesis. Dev Cell. 
2008; 15:261–71.
14. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 
family: genomics, cell biology, and relevance to renal and 
cardiovascular injury. Physiol Genomics. 2012; 44:237–44.
15. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, 
West KM, et al. Widespread microRNA repression by Myc 
contributes to tumorigenesis. Nat Genet. 2008; 40:43–50.
16. Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, 
Fernandez-Zapico ME. Transcriptional suppression of 
miR-29b-1/miR-29a promoter by c-Myc, hedgehog, and 
NF-kappaB. J Cell Biochem. 2010; 110:1155–64.
17. Gong J, Li J, Wang Y, Liu C, Jia H, Jiang C, et al. 
Characterization of microRNA-29 family expression and 
investigation of their mechanistic roles in gastric cancer. 
Carcinogenesis. 2014; 35:497–506.
18. Wang H, Zhu Y, Zhao M, Wu C, Zhang P, Tang L, et al. 
miRNA-29c suppresses lung cancer cell adhesion to extracel-
lular matrix and metastasis by targeting integrin β1 and matrix 
metalloproteinase 2 (MMP2). PLoS One. 2013; 8:e70192.
19. Stamatopoulos B, Meujeman N, Haibe-Kains B, Saussoy P, 
Van Den Neste E, Michaux L, et al. microRNA-29c and 
microRNA-223 down-regulation has in vivo significance in 
chronic lymphocytic leukemia and improves disease risk 
stratification. Blood. 2009; 113:5237–45.
20. Santarpia L, Calin GA, Adam L, Ye L, Fusco A, Giunti S, 
et al. A miRNA signature associated with human metastatic 
medullary thyroid carcinoma. Edocr Relat Cancer. 2013; 
20:809–23.
Oncotarget9949www.impactjournals.com/oncotarget
21. Presneau N, Eskandarpour M, Shemais T, Henderson S, 
Halai D, Tirabosco R, et al. MicroRNA profiling of periph-
eral nerve sheath tumours identifies miR-29c as a tumour 
suppressor gene involved in tumour progression. Br J 
Cancer. 2013; 108:964–72.
22. Bae HJ, Noh JH, Kim JK, Eun JW, Jung KH, Kim MG, 
et al. MicroRNA-29c functions as a tumor suppressor by 
direct targeting oncogenic SIRT1 in hepatocellular carci-
noma. Oncogene. 2014; 33:2557–67.
23. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, et al. 
Effects of microRNA-29 on apoptosis, tumorigenecity, and 
prognosis of hepatocellular carcinoma. Hepatology. 2010; 
51:836–45.
24. Zhi F, Zhou G, Wang S, Shi Y, Peng Y, Shao N, et al. 
A microRNA expression signature predicts meningioma 
recurrence. Int J Cancer. 2013; 132:128–36.
25. Liu N, Tang LL, Sun Y, Cui RX, Wang HY, Huang BJ, 
et al. MiR-29c suppresses invasion and metastasis by tar-
geting TIAM1 in nasopharyngeal carcinoma. Cancer Lett. 
2013; 329:181–8.
26. Sengupta S, den Boon JA, Chen IH, Newton MA, 
Stanhope SA, Cheng YJ, et al. MicroRNA 29c is down-
regulated in nasopharyngeal carcinomas, up-regulating 
mRNAs encoding extracellular matrix proteins. Proc Natl 
Acad Sci U S A. 2008; 105:5874–8.
27. Ding DP, Chen ZL, Zhao XH, Wang JW, Sun J, Wang Z, 
et al. miR-29c induces cell cycle arrest in esophageal 
 squamous cell carcinoma by modulating cyclin E expres-
sion. Carcinogenesis. 2011; 32:1025–32.
28. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, 
Mercer WE, et al. Wip1, a novel human protein phospho-
tase that is induced in response to ionizing radiation in a 
p53-dependent manner. Proc Natl Acad Sci U S A. 1997; 
94:6048–53.
29. Choi J, Appella E, Donehower LA. The structure and 
expression of the murine wild type p53-induced phospho-
tase 1 gene. Genomics. 2000; 64:298–306.
30. Lu X, Ma O, Nguyen TA, Jones SN, Oren M, Donehower LA. 
The Wip1 phosphotase acts as a gatekeeper in the p53-Mdm2 
autoregulatory loop. Cancer Cell. 2007; 12:342–54.
31. Batchelor E, Mock CS, Bhan I, Loewer A, Lahav G. 
Recurrent initiation. A mechanism for triggering p53 pulses 
in response to DNA damage. Mol Cell. 2008; 30:277–89.
32. Crescenzi E, Raia Z, Pacifico F, Mellone S, Moscato F, 
Palumbo G, et al. Down-regulation of wild-type p53-induced 
phosphotase 1 (Wip1) plays a critical role in regulating sev-
eral p53-dependent functions in premature senescent tumor 
cells. J Biol Chem. 2013; 288:16212–24.
33. Koturbash I, Zemp FJ, Kutanzi K, Luzhna L, Loree J, 
Kolb B, et al. Sex-specific microRNAome deregulation in 
the shielded bystander spleen of cranially exposed mice. 
Cell Cycle. 2008; 7:1658–67.
34. Honore HB, Bentzen SM. A modelling study of the 
potential influence of low-dose hyper-radiosensitivity 
on radiation treatment planning. Radiother Oncol. 2006; 
79:115–21.
35. Marples B, Cann NE, Mitchell CR, Johnston PJ, Joiner 
MC. Evidence for the involvement of DNA-dependent 
protein kinase in the phenomena of low dose hyper- 
radiosnesitivity and increased radioresistance. Int J Radiat 
Biol. 2002; 78:1139–47.
36. Lin PS, Wu A. Not all 2 Gray radiation prescriptions are 
equivalent: cytotoxic effect depends on delivery sequences 
of partial fractionated doses. Int J Radiat Oncol Biol Phys. 
2005; 63:536–44.
37. Krause M, Wohlfarth J, Georgi B, Pimentel N, Dorner D, 
Zips D, et al. Low-dose hperradiosensitivity of human 
 glioblastoma cell lines in vitro does not translate into 
improved outcome of ultrafractionated radiotherapy in vivo. 
Int J Radiat Biol. 2005; 81:751–8.
38. Short S, Mayes C, Woodcock M, Johns H, Joiner MC. Low 
dose hypersensitivity in the T98G human glioblastoma cell 
line. Int J Radiat Biol. 1999; 75:847–55.
39. Polager S, Ginsberg D. p53 and E2f: partners in life and 
death. Nat Rev Cancer. 2009; 9:738–48.
40. Wang B, Li D, Kovalchuk O. p53 Ser phosphorylation and 
histone modifications contribute to IR-induced miR-34a 
transcription in mammary epithelial cells. Cell Cycle. 2013; 
12:2073–83.
41. Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miR-
NAs activate p53 by targeting p85 alpha and CDC42. Nat 
Struct Mol Biol. 2009; 16:23–9.
42. Catalano A, Rodilossi S, Caprari P, Coppola V, Procopio A. 
5-Lipoxygenase regulates senescence-like growth arrest by 
promoting ROS-dependent p53 activation. EMBO J. 2005; 
24:170–9.
43. Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, 
Agarwal R. p21 and p27 induction by silibinin is essential 
for its cell cycle arrest effect in prostate carcinoma cells. 
Mol Cancer Ther. 2007; 6:2696–2707.
44. Cregan SP, MacLaurine JG, Craig CG, Robertson GS, 
Nicholson DW, Park DS, et al. Bax-dependent caspase-3 
activation is a key determinant in p53-induced apoptosis in 
neurons. J Neurosci. 1999; 19:7860–9.
45. Cullen SP, Martin SJ. Caspase activation pathways: some 
recent progress. Cell Death Differ. 2009; 16:935–8.
46. Zhang JX, Qian D, Wang FW, Liao DZ, Wei JH, Tong ZT, 
et al. MicroRNA-29c enhances the sensitivities of human 
nasopharyngeal carcinoma to cisplatin-based chemotherapy 
and radiotherapy. Cancer Lett. 2013; 329:91–8.
47. Hu Z, Klein JD, Mitch WE, Zhang L, Martinez I, Wang XH. 
MicroRNA-29 induces cellular senescence in aging muscle 
through multiple signaling pathways. Aging (Albany NY). 
2014; 6:160–75.
Oncotarget9950www.impactjournals.com/oncotarget
48. Lowe J, Cha H, Lee MO, Mazur SJ, Appella E, Fornace 
AJJr. Regulation of the Wip1 phosphotase and its effects on 
the stress response. Front Biosci. 2012; 17:1480–98.
49. Le Guezennec X, Bulavin DV. WIP1 phosphotase at the 
crossroads of cancer and aging. Trends Biochem Sci. 2010; 
35:109–14.
50. Fuku T, et al. Increased wild-type p53-induced phosphotase 
1 (Wip 1 or PPM1D) expression correlated with downregu-
lation of checkpoint kinase 2 in human gastric carcinoma. 
Pathol Int. 2007; 57:566–71.
51. Saito-Ohara F, et al. PPM1D is a potential target for 17q 
gain in neuroblastoma. Cancer Res. 2003; 63:1876–83.
52. Castellino RC, et al. Medulloblastomas overexpress the 
p53-inactivating oncogene WIP1/PPM1D. J Neurooncol. 
2008; 86:245–56.
53. Tan DS, et al. PPM1D is a potential therapeutic target 
in ovarian clear cell carcinomas. Clin Cancer Res. 2009; 
15:2269–80.
54. Loukopoulos P, et al. Genome-wide array-based compara-
tive genomic hybridization analysis of pancreatic adeno-
carcinoma: identification of genetic indicators that predict 
patient outcome. Cancer Sci. 2007; 98:392–400.
55. Bulavin DV, et al. Amplification of PPM1D in human 
tumors abrogates p53 tumor-suppressor activity. Nat Genet. 
2002; 31:210–5.
56. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. p53 
gene mutation in hepatocellular carcinoma. Cancer Res. 
1992; 52:6358–64.
57. Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, 
Benner A, Stange DE, et al. Genomic and protein expres-
sion profiling identifies CDK6 as novel independent prog-
nostic marker in medulloblastoma. J Clin Oncol. 2005; 
23:8853–62.
58. Fan YC, Mei PJ, Chen C, Miao FA, Zhang H, Li ZL, et al. 
MiR-29c inhibits glioma cell proliferation, migration, inva-
sion and angiogenesis. J Neurooncol. 2013; 115:179–88.
59. Han TS, Hur K, Xu G, Choi B, Okugawa Y, Toiyama Y, 
et al. MicroRNA-29c mediates initiation of gastric carcino-
genesis by directly targeting ITGB1. Gut. 2014; May 28. 
(Epub ahead of print).
60. Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, 
Shepard MA, et al. Medulloblastomas overexpress the 
p53-inactivating oncogene WIP1/PPM1D. J Neurooncol. 
2008; 86:245–56.
61. Liang C, Guo E, Lu S, Wang S, Kang C, Chang L, et al. 
Overexpression of wild-type p53-induced phosphatase 1 
confers poor prognosis of patients with gliomas. Brain Res. 
2012; 1444:65–75.
62. Fuku T, Semba S, Yutori H, Yokozaki H. Increased wild-
type p53-induced phosphatase 1 (Wip 1 or PPM1D) expres-
sion correlated with downregulation of checkpoint kinase 2 
in human gastric carcinoma. Pathol Int. 2007; 57:566–71.
63. de Planell-Saguer M, Rodicio MC, Mourelatos Z. Rapid 
in situ codetection of noncoding RNAs and proteins in cells 
and formalin-fixed paraffin-embedded tissue sections with-
out protease treatment. Nat Protoc. 2010; 5:1061–73.
